Skip to main content

Table 4 Multivariable Cox regression model, including significant variables at the univariate analysis, and survival in bevacizumab-group

From: Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

Progression Free Survival (N = 111)
Characteristics Adjusted HR 95% CI P
Mucinous histology No 1   
  Yes 2.45 1.19-4.44 0.016
Previous adjuvant CT No 1   
  Yes 1.49 0.84-2.63 0.166
Resected primary tumor No 1   
  Yes 1.59 0.51-3.71 0.383
-1498 C- 1   
  T/T 2.28 1.16-4.19 0.018
Overall Survival (N = 111)
Characteristics Adjusted HR 95% CI p
Primary tumor Colon 1   
  Rectum 0.40 0.15-1.60 0.245
Mucinous histology No 1   
  Yes 4.22 1.60-9.27 0.009
Leukocytosis No 1   
  Yes 3.02 1.03-10.07 0.043
-1498 C- 1   
  T/T 2.22 0.54-5.51 0.195